Gestational diabetes mellitus (GDM) is associated with adverse maternal and neonatal outcomes. This study aimed to assess whether a composite, multidimensional compliance score—reflecting adherence to several management domains—was associated with glycemic control, maternal complications, and neonatal outcomes. The investigators also evaluated these associations after adjusting for potential confounders.
This is a retrospective cohort study including 360 women diagnosed with GDM between October 2023 and January 2026 at Guiyang Second People's Hospital. The analysis used routinely collected clinical and laboratory data from the study hospital and applied multivariate modeling to estimate associations between compliance and outcomes.
A weighted compliance score (range 1–3) was constructed from five management domains: blood glucose monitoring, diet, physical activity, prenatal visit attendance, and medication adherence. Based on this score, participants were categorized into three compliance groups: high, moderate, and low. The study treats this composite score as the primary exposure when assessing relationships with glycemic and perinatal outcomes.
The investigators used multivariate logistic regression models to evaluate associations between compliance groups and categorical outcomes. Models adjusted for pre-specified covariates: maternal age, body mass index (BMI), insulin use, and use of a mobile health application. Multiple comparisons were corrected using the Benjamini–Hochberg method. Specific model coefficients, confidence intervals, and full model diagnostics were not reported in the abstract.
Most baseline demographic and clinical variables were comparable across the three compliance strata. Exceptions included statistically significant differences in insulin therapy use and in utilization of a mobile health application between groups. The abstract does not list detailed distributions for all baseline variables, nor does it provide exact p-values for each comparison beyond noting these differences.
Achievement of glycemic targets varied markedly by compliance status. The proportion of women meeting glycemic targets was reported as:
Third-trimester HbA1c also differed across groups, with mean (± SD) values of:
These results indicate a graded relationship between higher management compliance and better biochemical glycemic markers.
In adjusted multivariate analyses, the study reports that low compliance (relative to high compliance) was independently associated with increased odds of several adverse neonatal outcomes, specifically:
All these associations were reported as statistically significant with p < 0.01. The abstract also reports that gestational weight gain was inversely associated with compliance level (higher compliance associated with lower weight gain). Exact adjusted odds ratios, confidence intervals, and absolute rates for each outcome beyond those described were not provided in the abstract.
Among 360 women with GDM managed at a single center, a higher weighted, multidimensional compliance score was linked to substantially better glycemic control—both in terms of target achievement and third-trimester HbA1c—and to lower adjusted risks of several adverse perinatal outcomes, including macrosomia, LGA, preterm delivery, and NICU admission. The authors conclude that integrated, comprehensive adherence across monitoring, lifestyle, prenatal care, and medication domains may improve both maternal metabolic control and neonatal outcomes.
The abstract reports a single-center, retrospective design and presents adjusted associations but does not provide full model estimates in the abstract. The publication date is August 27, 2026 (online ahead of print). Details such as the precise weighting algorithm for the compliance score, cutoff values defining high/moderate/low groups, and full adjusted effect estimates were not reported in the abstract and would require consulting the full text for complete methodological transparency.
The reported findings support the concept that multidimensional adherence in GDM management—encompassing blood glucose monitoring, diet, physical activity, prenatal visits, and medication adherence—correlates with improved glycemic metrics and fewer neonatal complications. The results underscore the potential value of comprehensive care models and adherence support, including mobile health tools, in GDM management. Further detail and confirmation would depend on the full article and prospective or interventional studies.